Arch Therapeutics Closes In On CE Mark For Novel Blood Control Agent

19 Aug 2016
News

Reed Miller @MedtechReed reed.miller@informa.com

Executive Summary

Securing the CE mark for its topical hemostatic agent has taken Arch Therapeutics longer than expected, but the company now predicts filing for a CE mark by the end of 2016, and is looking for a partner to help commercialize it in Europe.

Already Registered? Sign in to continue reading.

New to Medtech Insight? Start a free trial today!

Table
View full table

Topics

Related Companies

Arch Therapeutics Inc.

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

Dermatology Clinical Trials Research & Development

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

MT103735

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

MT103735

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Arch Therapeutics Closes In On CE Mark For Novel Blood Control Agent

News

Executive Summary

Related Content

Arch Therapeutics Targets mid-2016 For Commercial Launch Of AC5 Hemostatic Agent

Topics

Related Companies

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert